Propanc Bio Stock Price, News & Analysis

Propanc Biopharma (OTC-PINK:PPCB) has received a Notice of Allowance from the USPTO for a patent concerning a novel method to treat cancer stem cells (CSCs) using pancreatic proenzymes. This patent represents a significant advancement in the company's efforts to combat recurrent and metastatic cancer. The method specifically targets and eradicates CSCs, which are often resistant to conventional treatments. The patent is part of a portfolio comprising 65 patents globally. CEO James Nathanielsz highlighted the importance of expanding their intellectual property to enhance long-term shareholder value.

Propanc Biopharma (OTCQB: PPCB) announced its CEO, James Nathanielsz, advocates for proenzyme therapy as a key solution for cancer treatment. This comes alongside President Biden's initiative on lowering prescription drug costs through the 'Build Back Better Bill.' Proenzymes are sourced from bovine sources, offering a cost-effective, less severe alternative to existing cancer therapies. The company is preparing for clinical trials, aiming to reduce the financial burden on patients. Proenzyme therapy aims to target various solid tumors, potentially benefiting a large patient population.

Propanc Biopharma, Inc. (OTCQB: PPCB) has announced advancements in its cancer stem cell technology, PRP, which targets and eradicates cancer stem cells, crucial for combating metastatic cancer. Research indicates PRP regulates key biological pathways associated with cancer spread, potentially offering new hope for patients with solid tumors. CEO James Nathanielsz emphasized plans for a First-In-Human study in advanced cancer patients, following collaborative efforts in Spain and the US. These developments aim to reduce tumor recurrence, thus addressing a significant cause of cancer mortality.

Propanc Biopharma, Inc. (OTCQB: PPCB) announces a 13-year ongoing research partnership with the Universities of Jaén and Granada, Spain. The partnership aims to develop novel cancer treatments, focusing on their lead product candidate, PRP, which is advancing toward First-In-Human clinical studies. The collaboration has resulted in significant advances in drug development, including 5 scientific publications and a portfolio of 65 patents. Propanc's efforts are directed at targeting cancer stem cells to prevent tumor metastasis, with exciting prospects for further discoveries from their ongoing research programs.

Propanc Biopharma announced significant findings from Ms. Belen Toledo's thesis on proenzyme therapy for solid tumors. The research shows that proenzymes not only target cancer stem cells but also normalize the tumor microenvironment, promoting cell differentiation and potentially reversing malignant tumor phenotypes. These results, deemed pivotal by Chief Scientific Officer Dr. Julian Kenyon, support advancing their lead candidate, PRP, into clinical trials. The study is part of the POP1 program aimed at producing synthetic proenzymes at commercial scale, enhancing the company's innovative cancer treatment approach.

Propanc Biopharma, Inc. (OTCQB: PPCB) has entered into an equity purchase facility of up to $5 million with Dutchess Capital Growth Fund LP. The funds will support operations and advance the lead product, PRP, towards a First-In-Human study for advanced cancer patients. The company plans to establish a US-based R&D subsidiary, Cellmed Bio LLC, to identify strategic partnerships. The share issuance will be at a discount, with the right to sell shares contingent upon registering with the SEC. A registration statement will be filed within 45 days.

Propanc Biopharma, a biopharmaceutical company focused on cancer treatments, has appointed Paul Patrizio as Strategic Advisor to its executive team. He will facilitate the establishment of Cellmed Bio LLC, a wholly-owned research and development subsidiary in New Jersey, aimed at advancing the company's lead candidate, PRP, into clinical trials for metastatic cancer. This initiative is expected to enhance financing capabilities and resource allocation for clinical development.

Propanc Biopharma (OTCQB: PPCB) announced new research published in Expert Opinion on Biological Therapy, confirming the anti-tumor efficacy of pancreatic proenzymes, trypsinogen and chymotrypsinogen. The study shows these proenzymes can sensitize cancer stem cells (CSCs), enhancing the effectiveness of standard treatments like chemotherapy. Key findings include reduced CSC proliferation and migration, induction of cell differentiation, impaired angiogenesis, and decreased metastatic potential. The research supports proenzymes as a potential adjuvant therapy for late-stage cancer patients.

Propanc Biopharma, Inc. (OTCQB: PPCB) provided a shareholder update, highlighting confidence in a post-pandemic recovery. With improved economic conditions, the company is focusing on capital restructuring and advancing its lead product, PRP, towards a Phase I clinical study. The update emphasizes significant progress in scientific research, particularly in proenzyme therapy, and anticipates cash-back benefits from the Australian government for R&D. Strong institutional support is noted, alongside new therapeutic discoveries aimed at combating aggressive cancer types.